The growth-equity and late-stage heavy portfolio of the $116bn LP cratered at the beginning of the pandemic, but it largely made up lost ground and then some by mid-year, with Sequoia Capital's recovery standing out.
Apurva Mehta and Patrick O'Connor built a top-performing emerging manager VC portfolio while they were co-CIOs of a hospital endowment in Texas. Two years ago, they converted those partnerships into an FoF.
Biotech VCs have played a crucial role in developing medicines for the disorder before selling them to big pharma, and they've realized exceptional returns while making a difference in patients' lives.
Since launching its formal LP effort in 2016, Boulder, Colorado-based Foundry Group firm has backed dozens of emerging managers. These relationships have also helped the firm zero in on direct investments.